Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISB 1342 in relapsed/refractory multiple myeloma
NCT03309111Phase 1Completed
- Sponsor
- Ichnos Sciences Inc.
- Start
- Oct 2017
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ISB 1342 in multiple myeloma (MM), sponsored by Ichnos Sciences Inc. Primary endpoints: Maximal Tolerated Dose and/or Recommended Part 2 Dose at 28 days and Objective Response Rate at 28 days. Started Oct 2017; status: completed.
02
Drugs
ISB 1342
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03309111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03309111.